TY  - JOUR
AU  - Sanz Gómez, Marta
AU  - Manzano Lista, Francisco Javier
AU  - Vega Martín, Elena
AU  - González Moreno, D.
AU  - Alcalá, M.
AU  - Gil Ortega, Marta
AU  - Somoza, Beatriz
AU  - Pizzamiglio, C.
AU  - Ruilope Urioste, Luis Miguel
AU  - Aránguez, I.
AU  - Kolkhof, P.
AU  - Kreutz, R.
AU  - Fernández Alfonso, María Soledad
PY  - 2023
DO  - 10.1016/j.biopha.2023.115661
SN  - 0753-3322
UR  - https://hdl.handle.net/20.500.14352/110925
T2  - Biomedicine & Pharmacotherapy
AB  - The non-steroidal mineralocorticoid receptor antagonist (MRA) finerenone (FIN) improves kidney and cardiovascular outcomes in patients with chronic kidney disease (CKD) in type 2 diabetes (T2D). We explored the effect of FIN in a novel model of type 1...
LA  - eng
M2  - 1
PB  - Elsevier
KW  - Chronic kidney disease
KW  - Type 1 diabetes
KW  - Streptozotocin
KW  - Finerenone
KW  - Bone morphogenetic proteins
KW  - Perivascular adipose tissue
KW  - Perirenal adipose tissue
KW  - Vascular disease
TI  - Finerenone protects against progression of kidney and cardiovascular damage in a model of type 1 diabetes through modulation of proinflammatory and osteogenic factors
TY  - journal article
VL  - 168
ER  -